Silexion Therapeutics Corp (SLXN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 29, 2024, covering events occurring on November 27, 2024. Silexion Therapeutics Corp, a Cayman Islands emerging growth company, reported the completion of a 1-for-9 reverse share split of its ordinary shares and corresponding adjustments to its outstanding warrants.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Reverse Share Split: Effective after the close of trading on November 27, 2024, the company executed a 1-for-9 reverse split. The number of issued and outstanding ordinary shares decreased by a ratio of 1-for-9.
- Capital Structure: Authorized share capital remains at $20,000, now consisting of 22,222,222 ordinary shares. The par value per share increased from $0.0001 to $0.0009.
- Warrant Adjustments:
- Shares issuable per warrant decreased to 1/9th of an ordinary share.
- Exercise price increased nine-fold to $103.50 per post-split ordinary share.
- Fractional shares will be rounded up to the nearest whole number upon exercise, subject to payment of the full exercise price for the rounded amount.
- Trading Details: Ordinary shares began trading on a split-adjusted basis on November 29, 2024, under the existing ticker SLXN with a new CUSIP (G1281K 122). Warrants continue to trade under SLXNW with CUSIP G1281K 114.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary of the Memorandum Amendment is qualified by reference to the full document. The primary focus is the mechanical execution of the shareholder-approved reverse split.
Key Facts for Investor Verification
- Verify the adjusted number of shares held in brokerage accounts following the 1-for-9 split.
- Confirm the updated warrant exercise price of $103.50 and the reduced share entitlement (1/9th share per warrant).
- Check the new CUSIP number for ordinary shares (G1281K 122) to ensure proper settlement.
- Review the rounding policy for fractional shares resulting from warrant exercises.